Clinical trials: Memory
Alzheimer's Disease, Dementia
Efficacy and Safety of Aricept in the Treatment of Severe Alzheimer's Disease
Donepezil hydrochloride (Aricept) has been approved to treat symptoms associated with mild to moderate Alzheimer's disease (AD).
- Trial name
- NCT00096473
- Testing
- Donepezil hydrochloride
- Where
- 42 sites in United States, Australia and 4 more
- Volunteers
- 229 people
- Sponsor
- Eisai Inc.
Memory Loss
The Evaluation of the Efficacy and Safety of Donepezil Hydrochloride in Subjects With Mild Cognitive Impairment (MCI)
To investigate the efficacy and safety of donepezil in individuals with mild cognitive impairment on measures of cognition, global function and behavior.
- Trial name
- NCT00293176
- Testing
- Donepezil Hydrochloride
- Where
- 54 sites in United States
- Volunteers
- 821 people
- Sponsor
- Eisai Inc.
Alzheimer Disease, Dementia
A Study of the Safety and Effectiveness of Galantamine in Patients With Alzheimer's Disease
The purpose of this study is to evaluate the long-term efficacy and safety of galantamine in patients with Alzheimer's disease.
- Conditions
- Alzheimer Disease, Dementia, Mental Disorders, Brain Diseases
- Trial name
- NCT00216502
- Testing
- galantamine hydrobromide
- Volunteers
- 254 people
- Sponsor
- Janssen-Cilag S.p.A.
Age-Related Memory Disorders
A Study to Evaluate The Effects Of a Multivitamin/Mineral With Ginko In Subjects With Age Associated Memory Impairment
A Study to evaluate the cognitive effects and tolerance of a Multi-Vitamin/Mineral Preperation containing Gingko in elderly subjects with age associated memory impairment.
- Trial name
- NCT01160692
- Testing
- Multivitamin/Multimineral/Ginkgo (BAY 81-2775)
- Where
- United Kingdom
- Volunteers
- 132 people, healthy volunteers welcome
- Sponsor
- Bayer
Alzheimer's Disease, Dementia
A Study Of Oral PF-01913539 In Patients With Mild To Moderate Alzheimer's Disease
The purpose of this study is to demonstrate the safety and efficacy of PF-01913539 in the treatment of patients with mild-to-moderate Alzheimer's Disease.
- Conditions
- Alzheimer's Disease, Dementia, Dimebon, Investigational Drug
- Trial name
- NCT01066481
- Testing
- PF-01913539 5 mg
- Sponsor
- Pfizer
Memory Impairment
The Efficacy of Phosphatidylserine-Omega3 in Elderly Subjects With Memory Impairment
The primary objective of this trial is to assess the ability of Phosphatidylserine-Omega3 to improve cognitive performance in elderly subjects with memory impairment.
- Trial name
- NCT00736034
- Testing
- Phosphatidylserine-Omega3 (SharpPS™-Gold)
- Where
- Israel
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Enzymotec
Age-Related Memory Disorders
Study of LX6171 in Elderly Volunteers With Age Associated Memory Impairment
The purpose of the study is to determine the safety, tolerability, and effectiveness of 2 dose levels of LX6171 given over 28 days in patients with Age Associated Memory Impairment (AAMI).
- Trial name
- NCT00691808
- Testing
- LX6171 High Dose, LX6171 Low Dose
- Where
- 2 sites in Netherlands
- Volunteers
- 103 people
- Sponsor
- Lexicon Pharmaceuticals
Age Associated Memory Impairment
The Efficacy of Phosphatidylserine-Omega3 in Elderly With Age Associated Memory Impairment
The primary objective of this trial is to assess the ability of an oral administration of Phosphatidylserine-Omega3 to improve attention and memory complaints in comparison to placebo in age associated memory impaired subjects.
- Trial name
- NCT00437983
- Testing
- PS-Omega3
- Where
- Israel
- Volunteers
- 157 people, healthy volunteers welcome
- Sponsor
- Enzymotec
Age-Related Memory Disorders
A Safety and Efficacy Study of Ispronicline (TC-1734-112) in Subjects With Age Associated Memory Impairment (AAMI)
The purpose of this Phase II study is to evaluate the efficacy and safety of ispronicline (TC-1734-112) compared to placebo (inactive substance pill) in patients with age associated memory impairment (AAMI).
- Trial name
- NCT00109564
- Testing
- ispronicline (nicotinic acetylcholine receptor agonist)
- Where
- 15 sites in United States
- Volunteers
- 174 people, healthy volunteers welcome
- Sponsor
- Targacept Inc.
Breast Cancer, Cognitive Symptoms
Computer-Based Training in Patients With Post-Chemotherapy Cognitive Impairment
The investigators hypothesize that continuous active interaction with environments that are demanding to sensory, cognitive, and motor systems, together with imbedded rewards for successful performance, will help improve memory…
- Conditions
- Breast Cancer, Cognitive Symptoms, Memory Disorders
- Trial name
- NCT00387062
- Testing
- Computer-based Cognitive Training
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Posit Science Corporation
Memory, Learning
Cognitive, Emotional, Physical and Psychosocial Effects of Panax Quinquefolius L
The purpose of this study is to determine the efficacy and safety of REMEMBER-fX (HT1001, an extract of Panax quinquefolius) in a human sample using standard clinical neuropsychological instruments and side effects rating scales.
- Conditions
- Memory, Learning, Attention, Cognition
- Trial name
- REMEMBER-fX (NCT00527969)
- Testing
- HT1001 extract of Panax quinquefolius L
- Where
- Canada
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- CV Technologies
Alzheimer's Disease
Study of the Effects of Current Drug Treatments on Levels of Certain Brain Chemicals in Alzheimer's Disease
Alzheimer's disease is a medical illness that damages the brain and causes problems with memory, mood and behavior. A substance called acetylcholine (ACh), which is naturally produced in the body, plays an important role in the…
- Trial name
- NCT00104442
- Testing
- Rivastigmine
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Novartis
Relapsing-Remitting Multiple Sclerosis
A fMRI(Functional Magnetic Resonance Imaging) Research Study to Learn More About Multiple Sclerosis and Individuals Potentially Experiencing Memory Difficulties
The purpose of this study is to determine if medication designed to improve memory will help patients with Multiple Sclerosis (MS) who are experiencing memory problems using fMRI to track brain activity.
- Trial name
- NCT00315367
- Testing
- Donepezil HCI (drug)
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Neurognostics
Fatigue, Neoplasms
D-MPH in the Treatment of Fatigue and Neurobehavioral Function Related to Chemotherapy in Adult Cancer Patients
To evaluate the efficacy of dexmethylphenidate (d-MPH) in the treatment of chemotherapy-related fatigue in adult cancer subjects.
- Trial name
- NCT00047476
- Testing
- dexmethylphenidate(d-mph)
- Where
- 21 sites in United States
- Volunteers
- 160 people
- Sponsor
- Celgene Corporation